Research programme: synthetic humanised camelid nanobodies - Curie Institute/THERAVECTYSAlternative Names: Synthetic humanised camelid single-domain antibodies - Curie Institute/THERAVECTYS
Latest Information Update: 20 May 2015
At a glance
- Originator Curie Institute
- Developer Curie Institute; THERAVECTYS
- Class Immunotherapies; Single-domain antibodies
- Mechanism of Action CD27 antigen inhibitors; Checkpoint kinase inhibitors; Cytotoxic T-lymphocyte antigen 4 inhibitors; Immunomodulators; PDCD 1 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Cancer